Researchers who used PET with flortaucipir or NAV4694 found that cognitively healthy adults who didn't take cardiovascular medications had elevated beta-amyloid deposition levels tied to significantly increased low-density lipoprotein and total cholesterol levels, coronary risk profile scores and systolic blood pressure, compared with those who were on cardiovascular medications, but beta-amyloid accumulation among those with CV drug intake didn't correlate with vascular risk factors. The findings in JAMA Network Open "suggest the importance of targeting both systemic vascular burden and amyloid-beta burden in interventional studies of healthy individuals at risk of Alzheimer's," researchers wrote.
PET study links CV drugs, reduced beta-amyloid burden
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.